From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN, USA
3 regimens on this page
3 variants on this page

Note: this page contains regimens specific to angiosarcoma.


Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.



All lines of therapy

Bevacizumab monotherapy


Study Dates of enrollment Evidence
Agulnik et al. 2012 (NU 04S1) 2005-08 to 2011-04 Phase 2

Targeted therapy

21-day cycles


  1. NU 04S1: Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. Epub 2012 Aug 21. link to original article contains dosing details in manuscript PubMed NCT00288015

Paclitaxel monotherapy


Study Evidence
Penel et al. 2008 (ANGIOTAX) Phase 2


Supportive therapy

28-day cycle for 6 cycles


  1. ANGIOTAX: Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. link to original article contains dosing details in manuscript PubMed

Pazopanib monotherapy


Study Dates of enrollment Evidence Comparator Comparative Efficacy
Jones et al. 2022 (TAPPAS) 2017-2019 Phase 3 (C) Pazopanib & Carotuximab Did not meet primary endpoint of PFS

Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.

Targeted therapy

Continued indefinitely


  1. TAPPAS: Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. link to original article link to PMC article contains dosing details in manuscript PubMed NCT02979899